SandboxAlonso: Difference between revisions
Jump to navigation
Jump to search
Line 106: | Line 106: | ||
{{familytree | | | | | B01 | | | | | | | | B02 | | | B01=<div style="float: left; text-align: left; width: 14em; padding:1em;"> | {{familytree | | | | | B01 | | | | | | | | B02 | | | B01=<div style="float: left; text-align: left; width: 14em; padding:1em;"> | ||
* [[Adenocarcinoma]]<br> | * [[Adenocarcinoma]]<br> | ||
* [[Large cell carcinoma]]<br> | * [[Large cell carcinoma of the lung]]<br> | ||
* Not specified non-small cell lung cancer</div>|B02=Squamous cell carcinoma}} | * Not specified non-small cell lung cancer</div>|B02=[[Squamous cell carcinoma of the lung|Squamous cell carcinoma]]}} | ||
{{familytree | | | | | |!| | | | | | | | | |!| | | }} | {{familytree | | | | | |!| | | | | | | | | |!| | | }} | ||
{{familytree | | | | | C01 | | | | | | | | C02 | | | C01=Perform specific [[EGFR]] and ALK mutation testing: What is the specific mutation?|C02=Is the patient smoker or former smoker?}} | {{familytree | | | | | C01 | | | | | | | | C02 | | | C01=Perform specific [[EGFR]] and ALK [[mutation]] testing: What is the specific [[mutation]]?|C02=Is the patient a smoker or former smoker?}} | ||
{{familytree | |,|-|-|-|+|-|-|-|.| | | | | |!| | |}} | {{familytree | |,|-|-|-|+|-|-|-|.| | | | | |!| | |}} | ||
{{familytree | D01 | | D02 | | D03 | | | | D04 | | | D01=Sensitizing [[EGFR]] mutation|D02=ALK mutation|D03=Negative [[EGFR]] and ALK|D04=[[Non small cell carcinoma of the lung medical therapy#Metastatic squamous cell carcinoma|Click here for the squamous cell carcinoma specific treatment]]}} | {{familytree | D01 | | D02 | | D03 | | | | D04 | | | D01=Sensitizing [[EGFR]] mutation|D02=ALK mutation|D03=Negative [[EGFR]] and ALK|D04=[[Non small cell carcinoma of the lung medical therapy#Metastatic squamous cell carcinoma|Click here for the squamous cell carcinoma specific treatment]]}} |
Revision as of 19:30, 20 June 2014
Stage IV
Is pleural or pericardial effusion present (suggestive of M1a) or are findings suggestive of systemic metastasis (M1b) present? | |||||||||||||||||||||||||||||||||||||||||||||
M1a | M1b | ||||||||||||||||||||||||||||||||||||||||||||
Perform the following tests:
| Perform the following tests:
| ||||||||||||||||||||||||||||||||||||||||||||
Is the liquid extracted positive for malignant cells? | Are findings suggestive of adrenal metastasis or brain metastasis? | ||||||||||||||||||||||||||||||||||||||||||||
Yes | No | Adrenal | Brain | ||||||||||||||||||||||||||||||||||||||||||
Local therapy
PLUS | Perform a needle aspiration biopsy for metastasis confirmation | Surgical resection + adjuvant radiation therapy Radiation therapy alone:
PLUS | |||||||||||||||||||||||||||||||||||||||||||
What is the TN stage of the lung tumor? | |||||||||||||||||||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||||||||||||||||
| Administer therapy for metastatic disease in case of not curable lung lesions (click here for the treatment of local and systemic metastasis and neoplastic recurrence) | ||||||||||||||||||||||||||||||||||||||||||||
Follow-up
Controls of history + physical exam and chest CT with or without contrast every 6-12 months (first 2 years), then annual controls | |||||||||||||||||||||||||
Is there evidence of local or regional recurrence OR systemic metastasis? | |||||||||||||||||||||||||
Local or regional recurrence | Systemic metastasis | ||||||||||||||||||||||||
Local or regional recurrence
What is the site of the recurrence? | |||||||||||||||||||||||||||||||||||||||||||
Bronchial obstruction | Mediastinal lymph node | Superior vena cava obstruction | Severe hemoptisis | Resectable tumor | |||||||||||||||||||||||||||||||||||||||
Surgical correction of the obstruction: laser therapy, stent or any other surgical procedure OR Radiation therapy (external-beam or brachytherapy) OR Photodynamic therapy | Has the patient received radiation therapy? | Chemotherapy + radiation therapy OR External-beam radiation therapy OR Superior vena cava stent collocation | Surgery OR Radiation therapy (external-beam or brachytherapy) OR Laser therapy, photodynamic therapy or tumor embolization | Tumor resection (preferred option) OR Radiation therapy (stereotactic ablative radiotherapy or external-beam radiation therapy) | |||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||||||
Administer systemic therapy | Administer chemotherapy + radiation therapy | ||||||||||||||||||||||||||||||||||||||||||
Are findings suggestive of disseminated disease present? | |||||||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||||||
Click here for the treatment of metastatic disease | Observation OR systemic therapy | ||||||||||||||||||||||||||||||||||||||||||
Systemic metastasis
What are the characteristics of the metastasis? | |||||||||||||||||||||||||||||||||||||||||||
Diffuse brain metastasis | Bone metastasis | Localized symptoms | Solitary metastasis | Multiple metastasis | |||||||||||||||||||||||||||||||||||||||
External-beam radiation therapy (palliative) | External-beam radiation therapy (palliative) + limb stabilization (prevention of pathological fractures) Denosumab or biophosphonate therapy should be considered | External-beam radiation therapy (palliative) | Click here for the treatment of stage IV M1b (solitary site metastasis) | Click here for the treatment of metastatic disease | |||||||||||||||||||||||||||||||||||||||
Click here for the treatment of metastatic disease | |||||||||||||||||||||||||||||||||||||||||||
Metastatic disease
What the specific subtype according to the specific histological characteristics of the tumor? | |||||||||||||||||||||||||||||||||||||||
| Squamous cell carcinoma | ||||||||||||||||||||||||||||||||||||||
Perform specific EGFR and ALK mutation testing: What is the specific mutation? | Is the patient a smoker or former smoker? | ||||||||||||||||||||||||||||||||||||||
Sensitizing EGFR mutation | ALK mutation | Negative EGFR and ALK | Click here for the squamous cell carcinoma specific treatment | ||||||||||||||||||||||||||||||||||||
Click here for the sensitizing EGFR mutation specific treatment | Click here for the specific therapy for the ALK mutation specific treatment | Click here for the treatment of negative sensitizing EGFR and ALK mutation metastatic disease | |||||||||||||||||||||||||||||||||||||